Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01039935
Other study ID # LVO-0684
Secondary ID
Status Completed
Phase N/A
First received December 23, 2009
Last updated September 5, 2012
Start date November 2009
Est. completion date August 2012

Study information

Verified date September 2012
Source Rockefeller University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Prior to the main study we will perform a pilot study on 60 subjects. The purpose of the pilot study is to identify the range of odor concentrations that will be used in the main study and to optimize the tasks performed in the main study.


Recruitment information / eligibility

Status Completed
Enrollment 512
Est. completion date August 2012
Est. primary completion date August 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

1. Age 18-50

2. Current non-smokers

Exclusion Criteria:

1. Current smokers

2. Allergy to fragrances or smells of any kind

3. Active head cold, upper respiratory infection, or seasonal nasal allergies

4. History of nasal health problems, including endoscopic nasal surgery for sinus conditions or polyp removal.

5. Pre-existing medical condition that has caused anosmia or near total loss of the sense of smell, such as: head injury, cancer therapy, radiation to head and neck, or alcoholism

Study Design

Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
United States The Rockefeller University New York New York

Sponsors (1)

Lead Sponsor Collaborator
Rockefeller University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of correct responses when discriminating between (-)-carvone and (+)-carvone, isovaleric acid and isobutyric acid, androstenone and androstadienone DNA sequence of ORs sensitive to these odors 3 years No
Secondary concentration at which odors need to be added to allow for discrimination; thresholds to all six odors; verbal descriptors assigned to all six odors 3 years No
See also
  Status Clinical Trial Phase
Completed NCT02118909 - Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects Phase 1
Completed NCT01055002 - A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers Phase 1/Phase 2
Completed NCT02058784 - Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects Early Phase 1
Completed NCT04099225 - Multiple Breath Washout (MBW) Using Sulfur Hexafluoride Reference Values and Influence of Anthropometric Parameters